Literature DB >> 17400719

Cardiac effects of endothelin receptor antagonism in endotoxemic pigs.

D Konrad1, M Haney, G Johansson, M Wanecek, E Weitzberg, A Oldner.   

Abstract

Myocardial depression in sepsis is frequently encountered clinically and contributes to morbidity and mortality. Increased plasma levels of endothelin-1 (ET-1) have been described in septic shock, and previous reports have shown beneficial effects on cardiovascular performance and survival in septic models using ET receptor antagonists. The aim of the current study was to investigate specific cardiac effects of ET receptor antagonism in endotoxicosis. Sixteen domestic pigs were anesthetized and subjected to endotoxin for 5 h. Eight of these pigs were given tezosentan (dual ET receptor antagonist) after 3 h. Cardiac effects were evaluated using the left ventricular (LV) pressure-volume relationship. Endotoxin was not associated with any effects on parameters of LV contractile function [end-systolic elastance (Ees), preload recruitable stroke work (PRSW), power(max)/end-diastolic volume (PWR(max)/EDV) and dP/dt(max)/end-diastolic volume (dP/dt(max)/EDV)] but with impairments in isovolumic relaxation (time constant for pressure decay, tau) and mechanical efficiency. Tezosentan administration decreased Ees, PWR(max)/EDV, and dP/dt(max)/EDV, while improving tau and LV stiffness. Thus, dual ET receptor antagonism was associated with a decline in contractile function but, in contrast, improved diastolic function. Positive hemodynamic effects from ET receptor antagonism in acute endotoxemia may be due to changes in cardiac load and enhanced diastolic function rather than improved contractile function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400719     DOI: 10.1152/ajpheart.01023.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  7 in total

1.  Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration.

Authors:  Ralf Geiger; Axel Kleinsasser; Stephan Meier; Nikolaus Neu; Werner Pajk; Victoria Fischer; Benedict Treml; Joerg I Stein; Alexander Loeckinger
Journal:  Intensive Care Med       Date:  2007-09-27       Impact factor: 17.440

2.  Selective endothelin-A receptor blockade attenuates endotoxin-induced pulmonary hypertension and pulmonary vascular dysfunction.

Authors:  Brent M Toney; Amanda J Fisher; Marjorie Albrecht; Angelia D Lockett; Robert G Presson; Irina Petrache; Tim Lahm
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

3.  Value of caffeic acid phenethyl ester pretreatment in experimental sepsis model in rats.

Authors:  Ozlem Alici; Havva Sahin Kavakli; Cemile Koca; Neriman Defne Altintas; Murat Aydin; Suleyman Alici
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

4.  Left ventricular function during porcine-resuscitated septic shock with pre-existing atherosclerosis.

Authors:  Benedikt L Nußbaum; Oscar McCook; Clair Hartmann; José Matallo; Martin Wepler; Elena Antonucci; Miriam Kalbitz; Markus Huber-Lang; Michael Georgieff; Enrico Calzia; Peter Radermacher; Sebastian Hafner
Journal:  Intensive Care Med Exp       Date:  2016-06-06

5.  Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury.

Authors:  Ryan P Watts; Ogilvie Thom; John F Fraser
Journal:  J Transplant       Date:  2013-04-15

6.  Does carbon monoxide treatment alter cytokine levels after endotoxin infusion in pigs? A randomized controlled study.

Authors:  Anna-Maja Aberg; Pernilla Abrahamsson; Göran Johansson; Michael Haney; Ola Winsö; Jan Erik Larsson
Journal:  J Inflamm (Lond)       Date:  2008-08-07       Impact factor: 4.981

7.  Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients.

Authors:  Oscar H M Lundberg; Lill Bergenzaun; Jörgen Rydén; Mari Rosenqvist; Olle Melander; Michelle S Chew
Journal:  Crit Care       Date:  2016-06-09       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.